• 대한방사선치료학회:학술대회논문집
• /
• 대한방사선치료학회 2005년도 춘계학술대회 초록집
• /
• pp.23-26
• /
• 2005

재발한 vulva tumor의 근접 치료에 있어서 정상조직의 장애와 tumor volume내의 dose uniformity는 치료성적에 매우 중요한 요인이다. 이를 개선하기 위하여 modified MUPIT applicator를 제작하여 modified MUPIT applicator의 적용에 대한 유용성을 평가하고자 한다. modified MUPIT applicator는 template, cylinder, interstitial needle로 구성되었으며, tumor volume을 정하기 위하여 CT를 시행하였다. CT image를 이용하여 interstitial needle의 삽입 위치를 확인하고 수술실에서 template 를 치료 부위에 고정을 시키고 cylinder를 vaginal cavity에 삽입한 후 interstitial needle을 tumor volume 내에 삽입 하였다. tumor volume내에서 interstitial needle의 정확한 위치를 확인하기 위하여 CT를 시행하였으며 orthogonal film을 이용하여 computer planning을 실시하였다. daily tumor dose는 600 cGy, BID로 3000 cGy를 조사하였으며 치료 시 rectal dose를 평가하기 위하여 TLD를 이용하여 anal verge를 기준으로 5개 지점에서 rectal dose를 측정하였다. rectal dose는 34.1 cGy, 57.1 cGy, 103.8 cGy, 162.7 cGy, 165.7 cGy로 측정되었으며 EBRT(whole pelvis RT), ICR과 overlap되는 지점은 34.1 cGy, 57.1 cGy로 매우 우수하게 평가되었다. 결론적으로 자체 제작한 modified MUPIT applicator 사용하여 interstitial brachytherapy를 시행함으로써 EBRT로 cover하기 어려운 환자의 tumor volume내에서 irregularity를 효율적으로 극복할 수 있었고 우수한 rectal dose 분포를 통하여 rectal complication의 발생 확률을 현저히 감소시킬 수 있었다.

• 대한골관절종양학회지
• /
• 제19권2호
• /
• pp.43-49
• /
• 2013

목적: 천골에 발생하는 드문 질환인 거대 세포종의 치료 방법에 따른 특성과 예후에 대하여 알아보고자 하였다. 대상 및 방법: 1990년부터 2012년까지 천골의 거대 세포종으로 진단받고 본원에서 치료받은 7명의 환자를 대상으로 하였다. 결과: 평균 연령은 23.6세였고, 남자가 2예, 여자가 5예였으며 평균 추시 기간은 52.3개월(15-73개월)이었다. 5명의 환자에서 병소내 절제술을, 1명의 환자에서 변연 절제술을 시행하였으며 수술적 치료를 시행하지 않은 1명은 방사선 치료만 시행하였다. 방사선 치료만을 시행한 환자와 변연 절제술을 시행한 환자는 국소 재발 없이 추시 중이다. 그 외 병소내 절제를 시행한 5명 중 1예는 한 번의 수술로, 다른 두 예는 두 차례 수술 후 재발 없이 추시 관찰 중이다. 나머지 두 예는 추가 치료에도 병변의 진행을 보였다. 결론: 천골 거대 세포종 환자의 치료법으로써 병소내 절제는 신경학적 손상을 최소화하면서 종양을 치료할 수 있는 방법 중 하나가 될 것으로 판단된다. 또한, 수술적 치료가 어려운 경우 방사선 치료가 대안으로 사용될 수 있다고 생각된다.

• 동의생리병리학회지
• /
• 제24권2호
• /
• pp.272-277
• /
• 2010

This experimental study was performed to investigate the antitumor effect of Egg white combined-Chalcanthite (InSan 4, IS4) in xenografted nude mice with NCI-H460 human lung cancer cell. We cultured NCI-H460 cell lines and xenografted them on nude mice. These mice were divided into 3 groups; group with dose of 45 mg/kg IS4 orally, group with dose of 90 mg/kg IS4 orally, and the control group. They had been raised and treated for 28 days. We checked their body weight, tumor weight and volume twice a week, and their absolute organ weight, microhistological observation and biochemical blood analysis at the final day by sacrificing them. We also calculated their tumor inhibition rate (IR), mean survival time and percent increase in life span (% ILS). In this study, we observed that all of the IS4 treated mice have tumor regression, dosage-dependently, compared to the control group. Tumor weight and volume of high dose treated mice were smallest. IR increased in IS4 in a dose-dependent manner. Mean survival time and percent increase in life span (% ILS) in high-dose IS4 treatment group were the highest of the three groups. There was no significant difference in biochemical blood analysis, alanine phopsphatase (ALP), Calcium, creatinine (CRE), alanine transferase (ALT), and aspartate transaminase (AST) levels. The urea nitrogen (UN) level results significantly decreased by IS4 45 and 90 mg/kg (IS4 45 mg/kg, IS4 90 mg/kg, p<0.01). IS4 may have potential anti-tumor effect in a solid tumor induced by NCI-H460 without remarkable side effects.

• 대한두경부종양학회지
• /
• 제5권1호
• /
• pp.31-38
• /
• 1989

The result of neutron therapy on head and neck cancer using KCCH -Cyclotron neutron which had been using from October 1986 to September 1989 in the Korea Cancer Center Hospital. Among the total of 27 patients the cases of malignant salivary gland tumor were 14 and the cases of advanced head and neck cancer of AJCC stage IV were 13. The local control rate was 80% in malignant salivary gland tumor and 46.2% in advanced head and neck cancer. The 2 year survival rate was 60% in malignant salivary gland tumor and 38.5% in advanced head and neck cancer. Although there was no significant difference in prognosis according to the pathologic types, squamous cell carcinoma revealed a pattern of poor prognosis. The major complication from the neutron therapy had developed 7.1% in malignant salivary gland tumor and 23.1% in advanced head and neck cancer. In conclusion, neutron therapy is superior in the treatment of malignant salivary gland tumor and also effective in the treatment of advanced head and neck cancer when it can avoid to treat some site of low tolerance.

• Biomolecules & Therapeutics
• /
• 제13권2호
• /
• pp.113-117
• /
• 2005

Organosulfur compounds have been shown to exert an anti-cancer activity. In an attempt to develop novel chemopreventive and anti-cancer agents for liver cancer, we synthesized allylthiopyridazine derivatives. We have previously shown that allylthiopyridazine derivatives exert inhibitory effects on proliferation, invasion and migration of SK-Hep-1 hepatocarcinoma cells in vitro. The in vivo anti-tumor effect of 3-methvl-6-allylthiopy-ridazine, named as K6, was also reported. In this study, we further investigated the preclinical anti-cancer efficacy of K6 for hepatocarcinoma using nude mice xenografted with Hep-G2 hepatocellular carcinoma cells. K6(20-100 mg/kg, orally administered everyday for 30 days) markedly decreased the tumor volume of Hep-G2 cell-transplanted nude mice as evidenced by ultrasonographic and plethysmogranhic analyses. The inhibitory effect on tumor volume was lower than that exerted by doxorubicin (2 mg/kg), intravenously injected) which was used as a positive control. This study shows that K6 efficiently suppresses xenograft tumor growth, revealing K6 as apotential anti-cancer agent for suppressing in vivo progression of liver cancer. Given that hepatocarcinoma is among the most prevalent and lethal malignancies and there is no effective treatment to date, our study may contribute to the potential drug development for liver cancer.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제16권3호
• /
• pp.359-370
• /
• 1994

The reconstruction of major head and neck defects must be an integral part of the overall cancer treatment plan. The priorities of surgical treatment of head and neck tumor are 1) local tumor control, 2) relief of pain, 3) avoidance of difficult dressing, 4) provision of oral continence, and 5) ability to swallow and manage saliva. The recent advances in reconstructive surgery including the development of musculocutaneous flaps and microvascular free tissue transfer have allowed the surgical restoration of head and neck tumor defects that previously were not possible. These techniques have provided the opportunity to undertake larger, more aggressive resection while at the same time permitting functional rehabilitation. The timing of reconstruction demands on the nature of the resection, the ability of the ablative and reconstructive teams to coordinate efforts, the overall health of the patients, the patient's needs and wishes. So, we report to emphasize current methods for restoring major head and neck tumor defects after tumor ablation, reviewing for the reconstructive operations, postoperative complications, and postoperative sequelae etc, of patients from Jan, 1990 to Dec, 1993.

• IMMUNE NETWORK
• /
• 제12권2호
• /
• pp.66-69
• /
• 2012

The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-${\gamma}$ and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.

• 한국동물학회지
• /
• 제24권2호
• /
• pp.59-64
• /
• 1981

SCK 腫瘍細胞에 대한 溫熱處理의 細胞致死效果는 in vitro의 경우보다 in vivo의 경우에 顯著하게 컸다. In vivo에서 溫熱處理한 후, 腫瘍을 그대로 放置해두면 腫瘍細胞는 어느 期間동안 계속해서 죽게 되며 腫瘍의 機能的인 血管容積도 마찬가지로 減少한다. In vivo에서 X線을 照射하기 前과 後 30分에 溫熱處理한 腫瘍細胞의 放射線生殘曲線은 溫熱處理하지 않은 對照群의 그것에 比해 기울기가 컸다. 結論的으로 腫瘍細胞에 대한 溫熱處理의 細胞致死效果가 in vitro에 비해서 in vivo의 경우에 크게 되는 것은 腫瘍의 內部環境에 연유하는 것으로 생각된다.

• 대한수의학회지
• /
• 제61권1호
• /
• pp.9.1-9.6
• /
• 2021

Factors such as location, volume, and the type of neoplasm complicate achieving tumor control. Electrochemotherapy (ECT) is a supplementary treatment for inoperable neoplasms in veterinary patients. Three dogs were diagnosed with a tumor. Two were squamous cell carcinoma (SCC), and the other was liposarcoma, each with a single tumor with the size range of 1 to 5 cm. The tumor locations were the cervical, oral, and abdominal cavity. ECT was selected as a treatment. Bleomycin was injected intratumorally at the dose of 0.5 to 1.0 mg/㎤. Five minutes after the injection, electric pulses applied in a sequence of eight pulses lasting 100 μsec each, were delivered in 1,000 V/cm. An evaluation was performed after 1 week, and the next session was administered 2 weeks later. In a patient with oral SCC, the tumor was in partial remission after two sessions of ECT. Another patient with SCC on her neck was showed complete remission after 2 weeks of ECT administration. A third patient showed stable disease for 8 weeks. Complications were mild and transient and included skin necrosis, edema, local pain, and gait disturbance. ECT is a valid adjuvant, especially for inoperable, cutaneous, or accessible intra-abdominal tumors.

• BMB Reports
• /
• 제55권1호
• /
• pp.39-47
• /
• 2022

Adoptive cell transfer (ACT), a form of cell-based immunotherapy that eliminates cancer by restoring and strengthening the body's immune system, has revolutionized cancer treatment. ACT entails intravenous transfer of either tumor-resident or peripheral blood-modified immune cells into cancer patients to mediate anti-tumor response. Although these immune cells control and eradicate cancer via enhanced cytotoxicity against specific tumor antigens, several side effects have been frequently reported in clinical trials. Recently, exosomes, potential cell-free therapeutics, have emerged as an alternative to cell-based immunotherapies, due to their higher stability under same storage condition, lower risk of GvHD and CRS, and higher resistance to immunosuppressive tumor microenvironment. Exosomes, which are nano-sized lipid vesicles, are secreted by living cells, including immune cells. Exosomes contain proteins, lipids, and nucleic acids, and the functional role of each exosome is determined by the specific cargo derived from parental cells. Exosomes derived from cytotoxic effectors including T cells and NK cells exert anti-tumor effects via proteins such as granzyme B and FasL. In this mini-review, we describe the current understanding of the ACT and immune cell-derived exosomes and discuss the limitations of ACT and the opportunities for immune cell-derived exosomes as immune therapies.